Life Healthcare Group Holdings (LHC) Q3 2026 TU earnings summary

Executive summary

• FY2026 earnings comparisons are distorted by the FY2025 disposal of Life Molecular Imaging (LMI), which generated a R2.4bn net gain.

• NEPS, which excludes non-trading items, is presented as a better measure of underlying southern African business performance.

Financial highlights

• Continuing operations NEPS for FY2026 expected at 106.3–111.3 cents, up 6%–11% against FY2025 reported and pro forma NEPS of 100.3 cents.

• Continuing operations EPS expected at 94.1–98.8 cents, up 0%–5% against FY2025 pro forma EPS of 94.1 cents.

• Continuing operations HEPS expected at 100.7–106.0 cents, down 1%–6% against FY2025 pro forma HEPS of 107.1 cents.

• Continuing and discontinued operations EPS expected at 84.2–97.3 cents, down 63%–68% against FY2025 reported EPS of 263.0 cents.

Outlook and guidance

• FY2026 results for the year ended 30 September 2026 were expected to be released on 26 November 2026.

• FY2026 earnings estimates were still being finalised at the time of the statement.